Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
REDWOOD CITY, Calif., May 01, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8th, 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Matthew Beck
Solebury Trout
[email protected]
(646) 378-2933
